Background and Objectives: Facial angiofibromas are disfiguring facial lesions, present in up to 80% of patients with tuberous sclerosis complex. Recent elucidation of the complex cell signaling pathways that are disrupted in tuberous sclerosis indicates that rapamycin may be successful in alleviating the appearance of these lesions. The objectives of the current study were to evaluate the safety of topically applied rapamycin in patients with tuberous sclerosis complex and to determine its potential effectiveness in treatment of facial angiofibromas. Patients and Methods: The study was a prospective, randomized, doubleblind, placebo-controlled study performed at the University of Texas Health Science Center at Houston. Study subjects were recruited from the patient populations at the University of Texas Tuberous Sclerosis Center of Excellence. All subjects were over the age of 13 years and had a diagnosis of
tuberous sclerosis complex. Subjects were excluded if they were using any form of rapamycin or if they were pregnant. Study subjects applied the study product to their facial angiofibromas nightly for a duration of 6 months. The investigational product contained one of three doses of rapamycin compounded with Skincerity Ò : (i) no rapamycin; (ii) 1 mg of rapamycin per 30 cc (0.003%); or (iii) 5 mg of rapamycin per 30 cc (0.015%). Plasma rapamycin concentrations were measured monthly to test for systemic absorption. Complete blood counts were performed monthly to test for anemia, neutropenia, or thrombocytopenia. Upon completion of the trial, subjects were asked if the formulation had improved the appearance of their facial angiofibromas. Results: Twenty-three subjects completed the study. There was no detectable systemic absorption of rapamycin (all blood concentrations were <1.0 ng/mL). There were no significant changes in white blood cell, red blood cell, or platelet counts. Seventy-three percent of subjects in the treatment arms versus 38% of subjects in the placebo arm reported a subjective improvement in the appearance of their facial angiofibromas. Conclusion: The application of low-dose topical rapamycin (0.003-0.015%) to the face can safely decrease the appearance of facial angiofibromas in patients with tuberous sclerosis complex.
Trial Registration: ClinicalTrials.gov Identifier: NCT01031901
Tuberous sclerosis complex (TSC) is an autosomal-dominant genetic disorder characterized by the formation of benign tumors in multiple organ systems. Facial angiofibromas appear as red or pink papules over the central face, especially on the nasolabial folds, cheeks, and chin, [1] in people with TSC. Lesions arise in early childhood and are present in up to 80% of TSC patients. [1, 2] In some patients, the lesions become confluent and can result in severe disfigurement. Although multiple treatments have been developed to alleviate the appearance of facial angiofibromas -curettage, cryosurgery, chemical peels, dermabrasion, shave excisions, and laser therapy [3] [4] [5] [6] [7] [8] -these are uncomfortable and need to be repeated at periodic intervals to treat recurrence. [9] In patients with TSC, the mammalian target of rapamycin (mTOR) is aberrantly activated in fibroblast-like cells located within the dermal layer of the skin. These cells produce an epidermal growth factor, epiregulin, which stimulates epidermal cell proliferation. [10] Epidermal cells are produced at a faster rate than the ability to slough the dead cells from the skin surface. [11] This overproduction of skin cells, in conjunction with angiogenesis, results in the initial appearance and continued progression of facial angiofibromas over time.
Recent elucidation of the complex signaling relationship between the tuberous sclerosis 1 (TSC1) and tuberous sclerosis 2 (TSC2) gene products and mTOR has led to an explosion of research related to the use of mTOR inhibitors, such as rapamycin, in TSC. These mTOR inhibitors are showing promise in treating multiple tumor types, including renal angiomyolipomas (AMLs), sub-ependymal giant cell astrocytomas (SEGAs), and lymphangioleiomyomatosis (LAM). [12] [13] [14] [15] Rapamycin is a naturally occurring antifungal macrolide, first isolated from Streptomyces hygroscopicus in 1965. Rapamycin binds with high specificity to mTOR, and binding results in inhibition of mTOR activity and ultimately in downregulation of cell growth. [16] Rapamycin has a molecular weight of 914.2 grams/mol, allowing for its absorption through the superficial layers of the epidermis to the deep dermal layer implicated in the development of facial angiofibromas.
The primary goal of this study was to evaluate the safety of topical rapamycin (0.003% and 0.015%) in patients with TSC. The secondary goal of this study was to evaluate the efficacy of the topical product for treatment of facial angiofibromas.
Methods

Patient Selection
After approval was obtained from the institutional review board at the University of Texas Health Science Center (UTHSC) at Houston, study subjects were recruited from the patient population at the Tuberous Sclerosis Center of Excellence at the University of Texas Medical School at Houston from January 2010 through August 2010. All subjects were over the age of 13 years and had a clinical diagnosis of tuberous sclerosis complex. [17] Subjects were excluded if they were currently pregnant, were using oral rapamycin, or had any form of immune dysfunction. After completing an informed consent document, willing participants who satisfied the inclusion and exclusion criteria (table I) were enrolled in the study. The study participants provided demographic data, including age, sex, and race, during the initial interview. Race/ethnicity was defined by the participants.
Protocol Summary
Upon enrollment, subjects were randomized and provided with a bottle of the investigational product. The investigational product contained one of three doses of rapamycin compounded with Skincerity Ò : (i) no rapamycin; (ii) 1 mg of rapamycin per 30 cc (0.003%); or (iii) 5 mg of rapamycin per 30 cc (0.015%). Subjects applied a thin coating of the investigational product to the skin directly over the treatment area every evening for 6 months. The product was allowed to air dry for 60 minutes following application and was removed by gentle washing in the morning. Subjects were monitored monthly in the study clinic, where blood was drawn to measure serum rapamycin concentrations, the study product was examined, and photographs were taken. The study product was replenished as needed.
Rapamycin concentrations were analyzed at the University of Texas Medical School at Houston rapamycin laboratory, using an Architect i1000 analyzer (Abbott Laboratories, Abbott Park, IL, USA).
The investigational product was manufactured at no cost by Biomedical Development Corporation (San Antonio, TX, USA) by combining sirolimus with Skincerity Ò . The company randomized the investigational product. The researchers and study subjects were not provided with the randomization information until all data had been collected. Biomedical Development Corporation had no role in the design of the trial; in the collection, analysis, or interpretation of the data; or in the writing of this manuscript. The authors vouch for the accuracy and completeness of the reported data.
Data Collection and Statistical Methods
Upon completion of the trial, subjects were asked if they ''got better on the treatment'', if Table I . Inclusion and exclusion criteria for study participation
Inclusion criteria
Male and female patients aged 13 years and older
Patients with a clinical diagnosis of tuberous sclerosis complex [17] and visible facial angiofibromas
Patients willing and able to comply with the requirements of the study
Exclusion criteria
Sexually active women of childbearing potential not using adequate contraception they ''got worse on the treatment'', or if ''the treatment made no difference''. Statistical analysis was performed using a two-sided Fischer's exact test. At each study visit, blood was drawn to measure serum rapamycin concentrations and complete blood counts to assess for systemic absorption of the study product.
Results
Patient Demographics
A total of 28 patients met the criteria for enrollment in the study: 15 men (54%) and 13 women (46%). The mean patient age at the time of study enrollment was 23 years; 72% of the patients were non-Hispanic Whites, 7% were Hispanic, 10% were African American, 7% were Asian, and 4% were Native American (table II) . No subject who was invited to participate refused. Two subjects withdrew from the study, secondary to discomfort with product application (a burning sensation with application). Two subjects were withdrawn by the investigators, secondary to poor compliance with study protocols. One subject was withdrawn following prolonged hospitalization unrelated to the study product. Twenty-three subjects completed the entire study protocol.
Rapamycin Concentrations
Blood was drawn at each study visit to measure serum rapamycin concentrations. The limit of quantitation of this immunoassay was 1.0 ng/mL, and no subject reached that concentration during treatment.
Complete Blood Counts
Complete blood counts were performed by Quest Laboratories. No subject demonstrated a significant change in the white blood cell count, hemoglobin level, or platelet count during treatment.
Lesion Appearance
Of the 23 subjects who completed the study, 73% in the treatment arms reported that ''they got better on the treatment'', versus 38% of subjects in the placebo arm ( figure 1) [p = 0.18]. Twenty-seven percent of subjects in the treatment arms reported that ''the treatment made no difference'', versus 62% of subjects in the placebo arm. No subject reported that they ''got worse on the treatment''. There was no statistically significant difference in the response between subjects on high-dose and low-dose treatment.
Serious Adverse Events
Among the study subjects, a serious single adverse event occurred in a patient in the low-dose arm of the study. This subject aspirated during a seizure and developed pneumonia, which progressed to septic shock. His rapamycin concentrations were undetectable at the time of hospital admission, and he was immediately withdrawn from the study. His illness required prolonged hospitalization, but he has since made a full recovery.
Discussion and Conclusion
TSC is a genetic disorder affecting 1 in 6000 individuals worldwide. It is characterized by abnormal skin pigmentation and tumor formation in multiple organ systems. Facial angiofibromas are benign skin tumors found on the faces of patients with TSC, and the angiofibromatous lesions appear as red or pink papules distributed over the central face, most notably on the nasolabial folds, Native American 1 0 0 1 [4] cheeks, and chin. Lesions appear in early childhood and are present in up to 80% of TSC patients, creating considerable cosmetic morbidity.
Since the initial descriptions of facial angiofibromas in the 19th century, multiple treatments have been developed, attempting to alleviate the appearance of these lesions, including curettage, cryosurgery, chemical peels, dermabrasion, shave excisions, and laser therapy. Although the majority of these treatments are initially effective, they are uncomfortable, and over time the lesions recur.
Recent case reports and small case series have demonstrated that a topical rapamycin formulation might be efficacious, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] but prior reports have consisted of small series without placebo arms. The primary goal of this study was to determine whether our topical formulation of rapamycin was safe for topical use in the treatment of facial angiofibromas in patients with TSC. The study was designed to see if application of the investigational product resulted in detectable systemic absorption of the rapamycin. The secondary goal of this study was to evaluate whether the topical product decreased the appearance of the facial angiofibromas after 6 months of usage, as self-reported by the subjects. Twenty-three study subjects applied either a placebo or the investigational product nightly to their lesions for 6 months. The study results showed that there were no serious adverse events related to the study product and there was no detectable systemic absorption of the rapamycin during the study period. This study was not powered to reach statistical significance, and although it did not, almost twice as many subjects in the combined treatment arms reported subjective improvements (73%) when compared with the placebo arm (38%). The observed effect could result from a treatment effect of the vehicle itself, but these results suggest that topical application of our study product is effective in improving the appearance of facial angiofibromas in people with TSC. Future studies will include more detailed monitoring of efficacy, including standardized photography and monthly quality-oflife questionnaires.
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